Biological marker for inflammation
AssigneeCan-Fite Biopharma Ltd.
InventorsPnina Fishman, Sara Bar-Yehuda, Lea Madi
Life of this patent
Estimating the term…
Abstract
Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A3AR agonist.
Claims11
A therapeutic method, comprising:
- a. determining the level of A3 adenosine receptor (A3AR) in a sample of white blood cells (WBCs) of a subject;
- and
- b. treating the subject only if said level is above a predefined threshold which is about twice the level of A3AR in WBC of healthy subjects;
- wherein
- (i) the subject is one that is known to have an inflammatory state,
- (ii) the treating comprises administering an anti-inflammatory agent to the subject, and
- (iii) the anti-inflammatory agent is N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA);
- wherein the treating step comprises treating the subject with an amount of IB-MECA that is effective to reduce the inflammatory state in said subject.
A method for anti-inflammatory therapeutic treatment of a subject known to have an inflammatory state that is the result of an autoimmune disease, the method comprising:
- a. determining the level of A3 adenosine receptor (A3AR) in a sample of white blood cells (WBCs) of the subject;
- and
- b. treating the subject with an anti-inflammatory agent only if the level is above a predefined threshold which is about twice the level of A3AR in WBC of healthy subjects;
- wherein the anti-inflammatory agent is N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA) and the amount of the A3AR agonist is effective to reduce the inflammatory state in said subject.
In a method for anti-inflammatory therapeutic treatment of a subject known to have an inflammatory state that is the result of an autoimmune disease, the method comprising treating the subject with an effective amount of N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA),
- wherein the improvement comprises selecting the subject to receive the anti-inflammatory therapeutic treatment if determined to have a level of A3 adenosine receptor (A3AR), in a sample of white blood cells (WBCs) of the subject, above a predefined threshold that is about twice the level of A3AR in WBC of healthy subjects, and withholding said treatment if determined to have a level of A3AR, in a sample of WBCs of the subject, below the predefined threshold.
A therapeutic method, comprising:
- a. determining the level of A3 adenosine receptor (A3AR) in a sample of white blood cells (WBCs) of a subject;
- and
- b. treating the subject only if said level is above a predefined threshold which is about twice the level of A3AR in WBC of healthy subjects;
- wherein
- (i) the subject is one that is known to have rheumatoid arthritis,
- (ii) the treating comprises administering an anti-inflammatory agent to the subject, and
- (iii) the anti-inflammatory agent is an A3AR agonist;
- wherein the A3AR agonist is N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA), and the amount of the A3AR agonist administered is effective to reduce the inflammatory state in said subject.
A method for anti-inflammatory therapeutic treatment of a subject known to have rheumatoid arthritis, the method comprising:
- a. determining the level of A3 adenosine receptor (A3AR) in a sample of white blood cells (WBCs) of the subject;
- and
- b. treating the subject with an anti-inflammatory agent only if the level is above a predefined threshold which is about twice the level of A3AR in WBC of healthy subjects;
- wherein the anti-inflammatory agent is an A3AR agonist N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA), and the amount of said A3AR agonist is effective to reduce the inflammatory state in said subject.
In a method for anti-inflammatory therapeutic treatment of a subject known to have rheumatoid arthritis, the method comprising treating the subject with an A3 adenosine receptor (A3AR) agonist,
- wherein the improvement comprises selecting the subject to receive the anti-inflammatory therapeutic treatment if determined to have a level of A3AR, in a sample of white blood cells (WBCs) of the subject, above a predefined threshold that is about twice the level of A3AR in WBC of healthy subjects, and withholding said treatment if determined to have a level of A3AR, in a sample of WBCs of the subject, below said predefined threshold;
- wherein the A3AR agonist is N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA) and the amount of the A3AR agonist is effective to reduce the inflammatory state in said subject.
Dependencies are inferred from the claim text.